Eculizumab application during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: A case report with review of the literature

Eculizumab is highly effective in inhibiting complement activation and has successfully shown to prevent complications and to improve quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH). Its application during pregnancy showed favorable fetal and maternal outcome in the presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauritsch‐Hernandez, Lisa Sophie, Kraehenmann, Franziska, Balabanov, Stefan, Kimmich, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099006/
https://www.ncbi.nlm.nih.gov/pubmed/30147909
http://dx.doi.org/10.1002/ccr3.1634
Descripción
Sumario:Eculizumab is highly effective in inhibiting complement activation and has successfully shown to prevent complications and to improve quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH). Its application during pregnancy showed favorable fetal and maternal outcome in the presented case and has proven to be effective without raising safety concerns.

Ejemplares similares